Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study

Hepatic dysfunction may modify the safety profile and pharmacokinetics of docetaxel in cancer patients, but no validated guideline exists to guide dose modification necessitated by this uncommon comorbidity. We carried out the first prospective study of a personalized dosage regimen for cancer patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Syn, Nicholas Li‐Xun, Wang, Lingzhi, Wong, Andrea Li‐Ann, Soe, Mu‐Yar, Chuah, Benjamin, Chan, Daniel, Tan, Sing‐Huang, Soo, Ross Andrew, Lee, Soo‐Chin, Goh, Boon‐Cher, Yong, Wei‐Peng
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4768392/
https://ncbi.nlm.nih.gov/pubmed/26663719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12856
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller